{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-020527","form_type":"8-K","ticker":"CLNN","cik":"0001822791","company_name":"Clene Inc.","filed_at":"2022-10-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:52.359137+00:00","generated_at":"2026-06-22T21:52:32.680611+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Clene raises $10.8M in registered direct offering and secures $5M debt facility from Maryland","bullets":["Registered direct offering of 10,723,926 shares at $1.01/share; gross proceeds of $10.8M.","Proceeds to fund clinical development of CNM-Au8 for ALS and general corporate purposes.","Also entered $5M loan facility with Maryland DHCD (SSBCI), non-dilutive, conditional on matching equity.","Both transactions extend cash runway into Q3 2023; direct offering closing expected Nov 2, 2022.","Offering made to existing stockholders including board affiliates; no placement agent or commissions."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-020527","json":"https://secwatch.observer/filing/0000950170-22-020527.json","markdown":"https://secwatch.observer/filing/0000950170-22-020527.md","text":"https://secwatch.observer/filing/0000950170-22-020527.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1822791/000095017022020527/0000950170-22-020527-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1822791/000095017022020527/clnn-20221031.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T21:52:32.680611+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"92a0a96c12b5941afb2a5e77c9c866d2b6deede0","claim":"Clene Inc. entered into Securities Purchase Agreement with certain of the Company’s existing stockholders, including stockholders affiliated with directors of the Company (the “Purchasers”) valued at approximately $10.8 million (effective 2022-10-31).","evidence_excerpt":"On October 31, 2022, Clene Inc. (the “Company”) entered into securities purchase agreement (the “Securities Purchase Agreement”) with certain of the Company’s existing stockholders, including stockholders affiliated with directors of the Company (the “Purchasers”), pursuant to which the Company agreed to issue and sell, in a registered direct offering (the “Offering”), 10,723,926 shares of common stock, par value $0.0001 per share, at a sale price of $1.01 per share.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1822791/000095017022020527/0000950170-22-020527-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"certain of the Company’s existing stockholders, including stockholders affiliated with directors of the Company (the “Purchasers”)"},{"label":"Value","value":"approximately $10.8 million"},{"label":"Effective","value":"2022-10-31"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}